Clinical trial
Neoadjuvant Dose-Dense For Early Her2Neu Positive Breast Cancer
NCT03329378
Study timeline
Study start (actual)2019-01-24Date precision: day
Registry last updated2023-08-22
Observed by CureCurrent2026-10-07
Recorded dates are source observations, not predictions. Missing milestones are not estimated.
Conditions
Locally Advanced Breast Cancerunresolved
Interventions
DocetaxelDRUG · verified · RxNorm: docetaxel
CarboplatinDRUG · verified · RxNorm: carboplatin
TrastuzumabDRUG · verified · RxNorm: trastuzumab
PertuzumabDRUG · verified · RxNorm: pertuzumab
PegfilgrastimDRUG · verified · RxNorm: pegfilgrastim
TrastuzumabDRUG · verified · RxNorm: trastuzumab
PaclitaxelDRUG · verified · RxNorm: paclitaxel
DoxorubicinDRUG · verified · RxNorm: doxorubicin
CyclophosphamideDRUG · verified · RxNorm: cyclophosphamide
PaclitaxelDRUG · verified · RxNorm: paclitaxel
Sponsors & collaborators
Icahn School of Medicine at Mount Sinailead sponsor
Mapped research locations
Registry source
Open the source record to verify current eligibility, contacts, locations and registry updates.
Open NCT03329378 on ClinicalTrials.gov ↗Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.